Behavior of α-, β-, and γ-cyclodextrins and their derivatives on an in vitro model of blood-brain barrier

Abstract : Cyclodextrins (CDs) can be envisaged to cure some diseases related to the brain, but the behavior of these compounds toward the blood-brain barrier (BBB) remains largely unexplored to envisage such clinical applications. To fulfill this gap, the toxicity and endothelial permeability for native, methylated, and hydroxypropylated α-, β-, and γ-CDs have been studied on an in vitro model of BBB. As shown by the endothelial permeability for sucrose and immunofluorescence stainings, the native CDs are the most toxic CDs (α- > β- > γ-CD). Whereas the chemical modification of β-CD did not affect the toxicity of this CD, differences are observed for the α- and γ-CD. To determine the origin of toxicity, lipid effluxes on the brain capillary endothelial cells were performed in the presence of native CDs. It was found that α-CD removed phospholipids and that β-CD extracted phospholipids and cholesterol. γ-CD was less lipid-selective than the other CDs. Finally, the endothelial permeability of each CD has been determined. Surprisingly, no structure/ permeability relationship has been observed according to the nature and chemical modifications of CDs.
Type de document :
Article dans une revue
Journal of Pharmacology and Experimental Therapeutics, American Society for Pharmacology and Experimental Therapeutics, 2004, 310 (2), p. 745-751
Liste complète des métadonnées

https://hal-univ-artois.archives-ouvertes.fr/hal-00537883
Contributeur : Wilfried Déplanques <>
Soumis le : vendredi 19 novembre 2010 - 15:52:57
Dernière modification le : jeudi 11 janvier 2018 - 15:10:57

Identifiants

  • HAL Id : hal-00537883, version 1

Collections

Citation

V. Monnaert, Sébastien Tilloy, Hervé Bricout, Laurence Fenart, Roméo Cecchelli, et al.. Behavior of α-, β-, and γ-cyclodextrins and their derivatives on an in vitro model of blood-brain barrier. Journal of Pharmacology and Experimental Therapeutics, American Society for Pharmacology and Experimental Therapeutics, 2004, 310 (2), p. 745-751. 〈hal-00537883〉

Partager

Métriques

Consultations de la notice

101